JPMorgan ups BridgeBio target, adds to Analyst Focus List

JPMorgan analyst Anupam Rama raised the firm’s price target on BridgeBio (BBIO) to $94 from $89 and keeps an Overweight rating on the shares. JPMorgan also added BridgeBio to its Analyst Focus List as a growth idea. With the Q4 Attruby metrics and positive top-line pivotal infigratinib achondroplasia results in February, BridgeBio shares should be in the $90s from a valuation perspective, the analyst tells investors in a research note. JPMorgan does not expect a generic tafamidis entry before December 2028. The firm says its physician survey supported steady uptake of Attruby in the newly-diagnosed ATTR-CM setting.